Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:United_States_federal_law
|
| gptkbp:administeredBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:alsoKnownAs |
gptkb:Orphan_Drug_Act
|
| gptkbp:citation |
gptkb:21_U.S.C._§_360bb_et_seq.
|
| gptkbp:criteria |
disease affecting fewer than 200,000 people in the U.S.
|
| gptkbp:dateEnacted |
1983
|
| gptkbp:defines |
orphan drug
|
| gptkbp:enactedBy |
gptkb:United_States_Congress
|
| gptkbp:partOf |
gptkb:Federal_Food,_Drug,_and_Cosmetic_Act
|
| gptkbp:provides |
grant funding for research
incentives for orphan drug development market exclusivity for 7 years tax credits for clinical testing |
| gptkbp:purpose |
to encourage development of drugs for rare diseases
|
| gptkbp:bfsParent |
gptkb:Orphan_Drug_Act_of_1983
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
21 U.S.C. § 360bb et seq.
|